{"cluster": 16, "subcluster": 6, "abstract_summ": "Renin-angiotensin-aldosterone inhibitors should be continued in patients in otherwise stable conditions who are at risk for or having COVID-19.Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation.Based on some publications that associate SARS-CoV-2 infection with the use of anti-hypertensive drug groups such as angiotensin-converting-enzyme inhibitors (e.g. enalapril) or angiotensin II receptor blockers (e.g. losartan), many patients from South America, Central America or Spain, have stopped or intend to interrupt their treatments with these drugs.The Swedish Society of Hypertension, Stroke and Vascular Medicine supports current recommendations that ongoing RAAS blockade should be maintained in patients with COVID-19.There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes.The scientific community has recently focused its attention on angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (COVID-19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting.In a large Israeli dataset of 14 520 individuals tested for SARS-CoV-2, angiotension-converting enzyme inhibitors and angiotensin-receptor blockers were not found to be associated with increased SARS-CoV-2 infection after adjusting for major confounders.", "title_summ": "Comment on \u201cOrgan\u2010protective Effect of Angiotensin\u2010converting Enzyme 2 and its Effect on the Prognosis of COVID\u201019\u201dAngiotension-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infectionCOVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker TherapyBreaking the Enigma Code of Angiotensin II Type 2 Receptor SignalingAnti-RAS drugs and SARS-CoV-2 infectionRenin-Angiotensin-Aldosterone Inhibitors and COVID-19Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19Activation of the Renin-angiotensin-aldosterone system is associated with Acute Kidney injury in COVID-19Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19Comment on \u201cOrgan\u2010protective effect of angiotensin\u2010converting enzyme 2 and its effect on the prognosis of COVID\u201019\u201dControversies of renin\u2013angiotensin system inhibition during the COVID-19 pandemicThe renin\u2013angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implicationsRAAS inhibitors do not increase the risk of COVID-19The Renin Angiotensin Aldosterone System and COVID-19Angiotensin receptor blockers and COVID-19COVID-19 \u2013 Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attacks?COVID-19 and RAS: Unravelling an Unclear RelationshipRenin-angiotensin system inhibitors in COVID-19.[Hypertension, RAAS blockade and risk in COVID-19 patients].A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).[Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?]What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?Therapy with agents acting on the renin-angiotensin system and risk of SARS-CoV-2 infection.Effects of ACE inhibitors and angiotensin receptor blockers].Angiotensin-(1-7) and Obesity: Role on cardiorespiratory fitness and COVID-19 implications.Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19.", "title_abstract_phrases": "The Swedish Society of Hypertension, Stroke and Vascular Medicine supports current recommendations that ongoing RAAS blockade should be maintained in patients with COVID-19.A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes.Renin-angiotensin-aldosterone inhibitors should be continued in patients in otherwise stable conditions who are at risk for or having COVID-19.Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation.The abbreviated description of the RAS suggests that its dysregulation may be at the center of COVID-19.RAAS inhibitors do not increase the risk of COVID-19According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in-hospital death among patients with COVID-19.The Renin Angiotensin Aldosterone System and COVID-19The ongoing pandemic has stimulated study of the Renin Angiotensin Aldosterone System (RAAS), and how it can be manipulated to treat COVID-19.The scientific community has recently focused its attention on angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor 1 (AT1R) inhibitors and their possible benefit/harms for patients infected by Coronavirus disease (COVID-19) who experience pneumonia, but there are still some doubts about the effects of these drugs in this setting.Based on some publications that associate SARS-CoV-2 infection with the use of anti-hypertensive drug groups such as angiotensin-converting-enzyme inhibitors (e.g. enalapril) or angiotensin II receptor blockers (e.g. losartan), many patients from South America, Central America or Spain, have stopped or intend to interrupt their treatments with these drugs."}